Listing in Hong Kong again adds "new forces", with the shadow of Maotai and Tencent behind.

Recently, the capital market has once again seen new developments, with two new third board delisted companies - Xiantong Pharma and Huaxida submitting applications to move to the main board of the Hong Kong Stock Exchange for listing. It is worth mentioning that Xiantong Pharma, as a leading company in nuclear medicine, has received strategic investment from Maotai Jinshi Fund. Huaxida, a supplier of Android TV smart terminals, also failed to list on the Beijing Stock Exchange and has now turned to listing on the Hong Kong Stock Exchange with the backing of Tencent, holding 3.13% of its shares. In fact, since last year, there has been a small wave of new third board companies listing in Hong Kong. There are companies like Xiantong Pharma and Huaxida that have delisted and moved to Hong Kong, as well as companies planning to list in Hong Kong while still on the third board, each with their own highlights. Analysts believe that the move of new third board companies to list in Hong Kong reflects both the companies' need for diversified financing channels and international development, as well as the attractiveness of the Hong Kong stock market for different types of companies.